The Diabetic Foot Ulcers Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Diabetic Foot Ulcers Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Diabetic Foot Ulcers Market.
Some of the key takeaways from the Diabetic Foot Ulcers Pipeline Report:
Companies across the globe are diligently working toward developing novel Diabetic Foot Ulcers treatment therapies with a considerable amount of success over the years.
Diabetic Foot Ulcers companies working in the treatment market are Topadur Pharma, Cynata Therapeutics, Transwell Biotech, Aposcience, Ilya Pharma, Microbion Corporation, MediWound, Paracrine, INC., NovaLead Pharma, and others, are developing therapies for the Diabetic Foot Ulcers treatment
Emerging Diabetic Foot Ulcers therapies in the different phases of clinical trials are- TOP-N53, CYP-006TK, TWB-103, APO-2, ILP100, MBN-101, EscharEx, Adipose-derived regenerative cells, Galnobax, and others are expected to have a significant impact on the Diabetic Foot Ulcers market in the coming years.
In May 2024, Regenerative medicine company RION administered the first dose in its Phase IIa clinical trial of the purified exosome product (PEP) for treating diabetic foot ulcers (DFUs). This multi-center, prospective, open-label, and randomized trial plans to enroll 40 participants. The trial’s objective is to evaluate the safety and effectiveness of PEP when applied topically to DFUs.
In April 2024, Cynata Therapeutics Limited has announced the completion of patient enrolment for its Phase 1 clinical trial of CYP-006TK for diabetic foot ulcers (DFU).
In March 2024, Omeza®, a regenerative skincare company specializing in marine-based therapies for chronic wounds, presented positive interim results from a diabetic foot ulcer (DFU) clinical trial. The trial showed that using Omeza® OCM™ combined with offloading weight from the affected foot achieved a 91 percent area reduction (PAR) in DFUs within twelve weeks and a 63 percent PAR within four weeks. PAR is regarded as a surrogate endpoint for complete wound healing, with a PAR of 50 percent at four weeks in diabetic wound patients being a strong predictor of eventual complete healing.
In August 2023, Aurealis Therapeutics announced the successful dosing of the first diabetic foot ulcer (DFU) patient in its DIAMEND phase 2 clinical study of AUP-16. This multi-center, single-blinded, randomized, placebo-controlled trial aims to assess the safety, tolerability, and efficacy of the recommended phase 2 dose of AUP-16 as a topical treatment for non-healing neuroischemic DFUs.
Diabetic Foot Ulcers Overview
Diabetic Foot Ulcers (DFUs) are a common and serious complication of diabetes, characterized by open sores or wounds that typically develop on the feet. These ulcers occur due to a combination of factors related to diabetes, including neuropathy (nerve damage), peripheral artery disease (reduced blood flow), and immune system deficiencies, which can impede the body’s ability to heal wounds.
Get a Free Sample PDF Report to know more about Diabetic Foot Ulcers Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/diabetic-foot-ulcers-pipeline-insight
Emerging Diabetic Foot Ulcers Drugs Under Different Phases of Clinical Development Include:
TOP-N53: Topadur Pharma
CYP-006TK: Cynata Therapeutics
TWB-103: Transwell Biotech
APO-2: Aposcience
ILP100: Ilya Pharma
MBN-101: Microbion Corporation
EscharEx: MediWound
Adipose-derived regenerative cells: Paracrine, INC.
Galnobax: NovaLead Pharma
Diabetic Foot Ulcers Route of Administration
Diabetic Foot Ulcers pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Parenteral
Intravenous
Subcutaneous
Topical
Diabetic Foot Ulcers Molecule Type
Diabetic Foot Ulcers Products have been categorized under various Molecule types, such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Diabetic Foot Ulcers Pipeline Therapeutics Assessment
Diabetic Foot Ulcers Assessment by Product Type
Diabetic Foot Ulcers By Stage and Product Type
Diabetic Foot Ulcers Assessment by Route of Administration
Diabetic Foot Ulcers By Stage and Route of Administration
Diabetic Foot Ulcers Assessment by Molecule Type
Diabetic Foot Ulcers by Stage and Molecule Type
DelveInsight’s Diabetic Foot Ulcers Report covers around 34+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Diabetic Foot Ulcers product details are provided in the report. Download the Diabetic Foot Ulcers pipeline report to learn more about the emerging Diabetic Foot Ulcers therapies
Some of the key companies in the Diabetic Foot Ulcers Therapeutics Market include:
Key companies developing therapies for Diabetic Foot Ulcers are – Medline, B. Braun, Organogenesis, 3M, Smith & Nephew, Molnlycke Health Care, ConvaTec, Coloplast, Integra LifeSciences, Essity (BSN Medical), and others.
Diabetic Foot Ulcers Pipeline Analysis:
The Diabetic Foot Ulcers pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Diabetic Foot Ulcers with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetic Foot Ulcers Treatment.
Diabetic Foot Ulcers key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Diabetic Foot Ulcers Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetic Foot Ulcers market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Diabetic Foot Ulcers drugs and therapies
Diabetic Foot Ulcers Pipeline Market Drivers
Rise in global prevalence of foot ulcers in diabetic patients, increasing research and development activities in the development of biologics, technological advancements are some of the important factors that are fueling the Diabetic Foot Ulcers Market.
Diabetic Foot Ulcers Pipeline Market Barriers
However, high cost of the advanced wound care therapies, adverse effects associated with the drugs and other factors are creating obstacles in the Diabetic Foot Ulcers Market growth.
Scope of Diabetic Foot Ulcers Pipeline Drug Insight
Coverage: Global
Key Diabetic Foot Ulcers Companies: Topadur Pharma, Cynata Therapeutics, Transwell Biotech, Aposcience, Ilya Pharma, Microbion Corporation, MediWound, Paracrine, INC., NovaLead Pharma, and others
Key Diabetic Foot Ulcers Therapies: TOP-N53, CYP-006TK, TWB-103, APO-2, ILP100, MBN-101, EscharEx, Adipose-derived regenerative cells, Galnobax, and others
Diabetic Foot Ulcers Therapeutic Assessment: Diabetic Foot Ulcers current marketed and Diabetic Foot Ulcers emerging therapies
Diabetic Foot Ulcers Market Dynamics: Diabetic Foot Ulcers market drivers and Diabetic Foot Ulcers market barriers
Request for Sample PDF Report for Diabetic Foot Ulcers Pipeline Assessment and clinical trials
Table of Contents
1. Diabetic Foot Ulcers Report Introduction
2. Diabetic Foot Ulcers Executive Summary
3. Diabetic Foot Ulcers Overview
4. Diabetic Foot Ulcers- Analytical Perspective In-depth Commercial Assessment
5. Diabetic Foot Ulcers Pipeline Therapeutics
6. Diabetic Foot Ulcers Late Stage Products (Phase II/III)
7. Diabetic Foot Ulcers Mid Stage Products (Phase II)
8. Diabetic Foot Ulcers Early Stage Products (Phase I)
9. Diabetic Foot Ulcers Preclinical Stage Products
10. Diabetic Foot Ulcers Therapeutics Assessment
11. Diabetic Foot Ulcers Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Diabetic Foot Ulcers Key Companies
14. Diabetic Foot Ulcers Key Products
15. Diabetic Foot Ulcers Unmet Needs
16 . Diabetic Foot Ulcers Market Drivers and Barriers
17. Diabetic Foot Ulcers Future Perspectives and Conclusion
18. Diabetic Foot Ulcers Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las vegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
